High-Purity Reagents for ALS Targeted Therapy & Neurodegeneration Research
Navigate the evolving SOD Cu-Zn therapeutic landscape with rigorously designed reagents. From Tofersen-mimicking ASO development to mutant-selective small molecule stabilizers, our sequence-verified proteins and validation tools address the critical challenge of distinguishing pathogenic mutations from wild-type antioxidant function.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SOD Cu-Zn drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SOD Cu-Zn Mutant Proteins (G93A, A4V, G85R, H46R) and WT High purity (>95%), Monomeric state validated by SEC. Endotoxin <1 EU/µg. Sequence Verified. | View SOD Cu-Zn Products |
| Gene Delivery | SOD Cu-Zn Lentivirus Premade Particles Full-length ORF for stable NSC-34 or iPSC-derived motor neuron lines. | View SOD Cu-Zn Products |
| Benchmark Ab | Anti-SOD Cu-Zn Recombinant Antibody Sequence-verified positive control for Western/IP and misfolded conformation detection. | View SOD Cu-Zn Products |
| Validator | SOD Cu-Zn siRNA Set (3 targets + control) For ASO mechanism verification and knockdown verification. | View SOD Cu-Zn Products |
| TDP-43 (TARDBP) | ALS Co-pathology Target Aggregation interactor and dual-target therapeutic rationale. | View TARDBP Products |
| C9orf72 | Primary genetic factor in ALS, ideal for combination screening. | View C9orf72 Products |
| SOD2 (Mn-SOD) | Mitochondrial Superoxide Dismutase Compensatory antioxidant pathway for combination studies. | View SOD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pathogenic Mutant vs WT Selectivity | G93A, A4V, G85R, H46R mutant proteins available with >95% purity; Strictly monomeric (SEC validated) to exclude pre-aggregated material |
| Neuroinflammation Artifact Control | Endotoxin <1 EU/µg; Low endotoxin essential for microglia activation and motor neuron survival assays |
| Cross-species Cyno/Mouse Translation | Human/Mouse/Rat ortholog proteins with sequence-verified identity for preclinical model validation |
| Aggregation Kinetics Standardization | High-purity monomeric starting material validated by analytical SEC; consistent batch-to-batch ThT baseline |
| Control Reagents | Clinical benchmark antibodies and validated siRNA included for assay standardization |
Live SOD Cu-Zn R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active SOD1-ALS Clinical Trials
- ➤ Latest Aggregation Mechanism Research
- ➤ Recent ASO & Stabilizer Patent Filings
Global Clinical Landscape & Future Outlook
The approval of Tofersen (Biogen/Ionis) in 2023 marked the first disease-modifying therapy for SOD1-ALS, validating antisense-mediated knockdown. However, the field is pivoting toward next-generation strategies: mutant-selective degradation (sparing wild-type antioxidant function), small molecule stabilizers that correct misfolding, and combination therapies addressing SOD1-TDP-43 co-pathology. As first-generation ASOs establish safety profiles, the competitive edge shifts to CNS delivery efficiency and mutant specificity assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO/SiRNA | Biogen, Ionis, Wave Life Sciences | SOD1-ALS (Genetic) | Knockdown Efficiency Assay (Need validated siRNA controls & SOD Cu-Zn specific antibodies) |
| Small Molecule Stabilizers | AstraZeneca (Alexion), Novartis, Denali | Sporadic ALS, SOD1-ALS | Thermal Shift Assay (Need monomeric mutant proteins with >95% purity; avoid aggregate artifacts) |
| Gene Therapy (AAV) | Novartis, MeiraGTx, UniQure | SOD1-ALS | Biodistribution Assay (Need species-specific protein standards for PK/PD) |
| Mutant-Selective Degraders | Preclinical Biotech | SOD1-ALS | Selectivity Panel (Need WT vs G93A/A4V protein panel for specificity screening) |